Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain  by Hane, Michael et al.
FEBS 16123 FEBS Letters 373 (1995) 265-268 
Interaction of peptides derived from the Fas ligand with the 
Fyn-SH3 domain 
Michael Hane a'**, Bente Lowin a'**, Manuel Peitsch b, Karin Becker a, Jtirg Tschopp a'* 
~Institute of Biochemistry, University of Lausanne, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland 
bGlaxo Institute for Molecular Biology, CH-1028 Plan les-Ouates, Switzerland 
Received 4 September 1995 
Abstract Interaction of the widely expressed Fas with its mem- 
brane-hound ligand (FasL) leads to rapid cell death via apoptosis. 
Io avoid pathological tissue damage, the activity of FasL requires 
tight regulation. Here, we report that the Src homology 3 (SH3) 
domain of Fyn binds to the proline-rich cytoplasmic region of 
lZasL. Binding of the SH3 domain occurs between amino acid 
rt~sidues 44-71 which contains several potential SH3 interaction 
sites. This binding is specific, as SH3 domains of Lck, Grb2 and 
ras-GAP bind only weakly or not at all. We suggest hat FasL 
activity may be modulated by SH3 domains of the src-like Fyn 
kinase. 
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1 Introduction 
The Fas (Apo-1) system plays an important role in T cell 
homeostasis [1]. Mutant mice lacking functional FasL (gld 
i lice) or Fas (lpr mice) develop lymphadenopathy and exhibit 
~, utoimmune disease symptomatology [24]. Together with per- 
l ) r in and granzymes, Fas contributes to the lytic activity of 
c ytolytic T cells [5-8]. 
FasL is a 40-kDa type II membrane protein [4,9]. A salient 
! ~'ature of FasL is its proline-rich cytoplasmic sequence which 
i, not observed in any other member of the TNF  family (Fig. 
1 ). Of the 28 residues proximal to the hydrophobic transmem- 
I-'rane region, 16 are highly conserved prolines. Short proline- 
J~ch motifs are known to interact with the src-homology region 
,~H3 present in a variety of proteins important in cytoskeletal 
~rchitecture or signal transduction [10]. Fyn and Lck are two 
,~H3-containing members of the src protein kinase family that 
re associated with T cell receptor (TcR) and CD4/CD8, re- 
spectively [11]. In this study, we investigated the possible inter- 
~ ction between SH3 domains and the proline-rich cytoplasmic 
~,egment of FasL. 
7. Materials and methods 
~1. Peptides 
Peptides were synthesized on a Applied Biosystems 431A synthesizer 
sing Fmoc chemistry. When required, peptides were coupled to CNBr- 
~ ctivated Sepharose beads (Pharmacia, Ziirich, Switzerland). 
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2.2. Interaction of recombinant SH3-domains with FasL-derived 
peptides 
Sepharose-bound peptide P7 (10 ¢tl of a 50:50 slurry, 5 ¢tg of immo- 
bilized peptide) was incubated with 3/tg (total input, L) of the various 
GST-fusion proteins (Santa Cruz Biotechnology, Santa Cruz, CA, and 
a gift from D. Cantrell, ICRF, London, UK) in a total volume of 50 
¢tl of incubation buffer (1% NP-40, 150 mM NaCI, 10 mM Tris-HC1, 
pH 7.4) and incubated for 2 h at 25°C. The beads were washed 3 x in 
incubation buffer, resuspended in sample buffer and subjeeted to SDS- 
PAGE (10%) [12]. For inhibition studies, soluble peptides (500 ¢tg) were 
included uring the 2 h incubation time. 
2.3. Interaction of cellular Fyn with FasL peptides 
Precleared supernatants of lysed PMA/ionomycin-stimulated sple- 
nocytes were incubated overnight at 4°C with FasL proline-rich peptide 
P7 (or with P64, DAYLKVFFGGQEFR as a control) coupled to 
Sepharose beads. Precipitated proteins were separated by SDS-PAGE 
(1 × 10 7 cell equivalent per sample) and examined by immunoblot anal- 
ysis using polyclonal antibodies against Fyn (Santa Cruz Biotechnol- 
ogy). In the inhibition experiments, the FasL P7 peptide (or control 
peptide P16, FAKLNCRLYRKANKSSKL) was included at a final 
concentration f 20 mg/ml. 
2.4. Molecular model of FasL-Fyn SH3 domain 
The experimental co-ordinates of SH3 domain of the Fyn proto- 
oncogene tyrosine kinase were obtained from the Brookhaven Protein 
Data Bank (entry 1SHF). The poly-proline type II helix co-ordinates 
were generated using knowledge-based protein modelling methods as 
implemented in the modelling tool ProMod [13]. The structure of the 
helix elements was deduced from the experimentally determined poly- 
proline peptide of cytochrome C-551 (residues 58-65, PDB entry: 
1CCH). The elements were assembled in a long 'rod' and the relevant 
residues mutated to reflect he FasL sequence. Two copies of the Fyn 
SH3 domain were docked interactively to the poly-proline peptide as 
defined by the recent experimental elucidation of SH3-peptide com- 
plexes. Limited energy minimization with CHARMM (500 cycles of 
conjugate gradient minimization) were used to idealize the stereochem- 
istry of the model and optimize the intermolecular contacts. The inter- 
action between the peptide SH3-domain and the peptide was continu- 
ous and presented no cavities as evidenced by solvent-accessible surface 
overlap analysis. 
3. Results and discussion 
We assessed the ability of the proline-rich region of FasL to 
bind various SH3-containing proteins. Mouse FasL peptide 
(residues 44-71, see Fig. 1) was coupled to Sepharose beads and 
incubated with the GST-SH3 fusion proteins of Fyn, Lck, Grb2 
and ras-GAP (Fig. 2A). The GST-Fyn-SH3 and GST-Fyn- 
SH3-SH2 fusion proteins strongly interacted with the FasL 
peptide, while weak binding was detected with the respective 
N- and C-terminal SH3 domains of Grb2. In contrast, no bind- 
ing of Lck or ras-GAP was observed. In order to exclude that 
the absence of binding of Lck was due to a partial folding of 
the respective GST-Lck-SH3 fusion protein, a peptide corre- 
sponding to residues 1142-1157 (KGTDEVPVPPPVPPRR) of 
mouse Sos l was analysed for its relative affinities to the SH3 
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Fig. 1. Interaction of proline-rich sequences of FasL with SH3 domains. Alignment of the mouse, rat and human sequences from the cytoplasmic 
region of the FasL [22]. Peptides ynthesized are indicated. P1 (residues 67-71 of mouse FasL), P2 (64-71), P3 (60-71), P4 (56-71), P5 (52-71), P6 
(48-71), P7 (44-71). Four potential SH3-binding motifs (P-X-X-P) are indicated, the one shown in Fig. 4 is underlined. 
domains. This peptide has been reported to interact with vari- 
ous SH3 domains including Lck and Fyn [14] and indeed, 
binding of the Sosl proline-rich peptide to Lck and Fyn was 
detected (Fig. 2B). 
To determine the structural motif mediating Fyn-binding, 
proline-rich peptides of distinct lengths (P1-P7, Fig. 1) were 
immobilized. Binding to Fyn-SH3 was observed with P3 which 
contains residues 60-71 of FasL (Fig. 3). P4 also interacted with 
Fyn-SH3, but interestingly, binding was not strengthened with 
peptides containing additional prolines (P5/P6). Maximal Fyn- 
SH3 precipitation was achieved with immobilized P7 suggesting 
that more than one recombinant Fyn-SH3 domain interacts 
with the immobilized peptides or that the conformation of 
SH3-binding motif was altered in the P7 peptide resulting in 
increased affinity. 
Similar results were obtained when the soluble proline-rich 
FasL peptides were used as competitive inhibitors (Fig. 3). A 
100-fold molar excess of FasL peptides partly or completely 
abolished FasL P7/GST-Fyn-SH3 interaction as long as the 
peptide included the PPPSQPLP sequence (P3-P4). In contrast, 
fyn 
A GST -SH3-SH2 
i L I I L I 
~n  Ick ra~GAP GRB GRB 
-SH3 -SH3 -SH2-SH3-SH2 -SH3(N) -SH3(C) 
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no inhibition was observed when the peptide nded with LPP 
(P2). 
Structural and mutagenic studies have revealed that the core 
peptides which associate with SH3 domains consist of seven 
residues and contain the P-X-X-P motif[l 5]. The FasL contains 
several potential binding motifs [16,17], four of which are indi- 
cated in Fig. 1. SH3-binding peptides adopt left-handed type 
II helices [16]. Thus, a molecular model of the proline-rich 
segment (residues 44-71) of FasL was constructed [13], based 
on the experimentally elucidated 3-D structure of the poly- 
proline type II helix present in cytochrome C-551. The resulting 
helix contains 9 turns and is 75 ]~ long (Fig. 4). A gap of at least 
30 ,~ remains between the FasL-bound Fyn-SH3 domain the 
fatty acid membrane anchor of Fyn. Consistent with our model, 
the SH3 domain of Fyn is preceded by 84 residues at the 
N-terminus. This would provide a sufficiently long structure 
capable of spanning the gap between membrane and SH3 do- 
main. 
We next investigated the interaction of cellular Fyn with the 
FasL-derived peptides. When the immobilized peptide P7 of 
FasL was incubated with extracts of activated splenocytes, Fyn 
was detected in immunoblots (Fig. 5), while no anti-Fyn-reac- 
tire band was seen when the cellular extracts were exposed to 
Sepharose beads to which an irrelevant peptide had been cou- 
pled. Moreover, Fyn-binding to FasL peptide P7 was inhibited 
by soluble P7 peptide while the control peptide was ineffective. 
Considering the dramatic effect seen after systemic delivery 
of anti-Fas antibodies to mice [18], a tight regulation of FasL 
surface xpression and activity is unquestionably important. In 
primary allogeneic cytolytic T cells, Fas-and perforin-mediated 
target cell death is highly polarized, sparing innocent bystander 
cells from killing [5]. Perforin is harbored in cytoplasmic gran- 
~]n 
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Fig. 2. (A) Interaction of the immobilized P7 peptide of FasL with 
various GST-SH3 domain fusion proteins. Fyn (SH3, 85-139), Fyn 
(SH3-SH2, 85-247), Lck (SH3, 54-120), ras-GAP (SH2-SH3-SH2, 
171-448), grb-N (SH3, 1-68) and grb-C (SH3, 156-199). Negative con- 
trol. GST non-fusion protein. L shows the total input of the respective 
fusion proteins. (B) As Fig. 2A, but the interaction of immobilized 
mouse Sos 1 peptide (residues 1142-1157) with the indicated GST-SH3 
fusion proteins was analysed. 
II 
II 
Fig. 3. Localization of SH3-binding motif. (Upper panel) Immobilized 
FasL peptides (P1 through P7, see Fig. 1) were incubated with GST- 
Fyn-SH3-SH2 and analysed by SDS-PAGE. (Lower panel) Inhibition 
of the interaction of immobilized FasL P7 with GST-Fyn-SH3-SH2 by 
soluble peptides P1 through P7. Peptides were added at a 100-fold 
excess relative to immobilized P7. The left-most band represents he 
interaction of the protein in the absence of any competitor peptide 
(lower panel) or the total input of protein (upper panel). 
M. Hane et al. IFEBS Letters 373 (1995) 265~68 267 
!Zig. 4. Molecular model of the proline-rich cytoplasmic segment of mouse FasL interacting with a SH3 domain of Fyn. The SH3 interaction sequence 
~hown binds in the forward (Class I) orientation [17], but their precise localization is putative. The SH3 domain shown binds to the PSQP (residues 
~8-61, see Fig. 1) motif of FasL (PXXP-motif). The proline-rich sequence of FasL is modeled in a poly-proline II helix conformation. The FasL 
)eptides used in this study (P1-P7, see fig. 1) are indicated indicated. Proline residues are coloured in red. 
:ales which are guided by microtubules to release their contents 
~nly towards the site of target cell contact [19]. The functional 
mportance of the FasL-Fyn interaction is unknown. However, 
me could envisage that this interaction may modulate the sur- 
i'ace expression of newly synthesized FasL. Secretory vesicles 
lhat have the poly-proline-rich sequence of FasL cytoplasmati- 
:ally exposed might be directly targeted to the cell surface via 
Fyn and/or Lck SH3 domains, both of which are known to cap 
~t the site of TcR receptor/target cell interaction [20]. This 
~mplies that the resulting polarized vesicle-cell membrane fu- 
sion could engender local exposure of other vesicle-harbored 
proteins, including adhesion molecules and cytokines [19]. Al- 
ternatively, FasL may follow the regular non-polarized secre- 
tory pathway. If this occurs, subsequent redistribution and 
retention of FasL by Fyn or other proteins containing SH3 
domains (our study does not exclude this possibility) could 
result in high local accumulation of the lytic ligand in the region 
around the activated TcR complex. Thus, SH3 domains may 
not only dictate the position of soluble signaling molecules 
within the cell, but also decide on the location of membrane 
proteins with respect o the docking site of an interacting cell. 
A recent report demonstrated that apical surface xpression of 
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Fig. 5. Precipitation of Fyn from splenocytes with immobilized FasL 
proline-rich peptide (P/7). Precipitates were analysed by immunoblot- 
ting using the respective antibodies. Control precipitates with an irrele- 
vant peptide (Immob, P64) were negative. Fyn interaction with immo- 
bilized P/7 was inhibited in the presence of soluble P7 peptide (Comp 
P/7), but not the P16 control peptide. Specificity of the anti-Fyn anti- 
body was confirmed by Western blots of whole splenocyte xtracts 
(Cell). 
the amiloride-sensitive sodium channel is dependent on its pro- 
line-rich SH3-binding domain [21]. This may even point to a 
more general mechanism whereby SH3-domains control sort- 
ing and localization of membrane proteins in specialized or 
polarized cells. However, more experiments are required to 
support his hypothesis. 
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